Literature DB >> 21134567

Summary statement: utility of molecular marker testing in thyroid cancer.

Linwah Yip1, Electron Kebebew, Mira Milas, Sally E Carty, Thomas J Fahey, Sareh Parangi, Martha A Zeiger, Yuri E Nikiforov.   

Abstract

The use of molecular markers for thyroid cancer diagnosis, prognosis, and surveillance have been an exciting area of study and change. Recent investigative focus on promising new markers will very likely lead to improvements in the diagnostic utility of fine needle aspiration biopsy (FNAB) in predicting malignancy, as well as provide more accurate prognostic information pre- and postoperatively. The 2010 Annual Meeting of the American Association for Endocrine Surgeons featured a symposium dedicated to molecular marker testing in thyroid cancer and its potential clinical applicability.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21134567      PMCID： PMC3052981          DOI： 10.1016/j.surg.2010.09.023

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


  23 in total

1.  Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

2.  Allelic loss in parathyroid neoplasia can help characterize malignancy.

Authors:  Jennifer L Hunt; Sally E Carty; John H Yim; Justin Murphy; Leon Barnes
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

3.  Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples.

Authors:  Mira Milas; Joyce Shin; Manjula Gupta; Tomislav Novosel; Christian Nasr; Jennifer Brainard; Jamie Mitchell; Eren Berber; Allan Siperstein
Journal:  Ann Surg       Date:  2010-10       Impact factor: 12.969

4.  The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers.

Authors:  Mira Milas; Peter Mazzaglia; Su-Ynn Chia; Mario Skugor; Eren Berber; Sethu Reddy; Manjula Gupta; Allan Siperstein
Journal:  Surgery       Date:  2007-02       Impact factor: 3.982

5.  Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.

Authors:  Dingxie Liu; Shuiying Hu; Peng Hou; David Jiang; Stephen Condouris; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Authors:  Electron Kebebew; Julie Weng; Juergen Bauer; Gustavo Ranvier; Orlo H Clark; Quan-Yang Duh; Daniel Shibru; Boris Bastian; Ann Griffin
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

7.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

8.  Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.

Authors:  Yoram Cohen; Eli Rosenbaum; Douglas P Clark; Martha A Zeiger; Christopher B Umbricht; Ralph P Tufano; David Sidransky; William H Westra
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

9.  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.

Authors:  Giuliana Salvatore; Riccardo Giannini; Pinuccia Faviana; Alessia Caleo; Ilenia Migliaccio; James A Fagin; Yuri E Nikiforov; Giancarlo Troncone; Lucio Palombini; Fulvio Basolo; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

10.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

Authors:  Cristiana Lupi; Riccardo Giannini; Clara Ugolini; Agnese Proietti; Piero Berti; Michele Minuto; Gabriele Materazzi; Rossella Elisei; Massimo Santoro; Paolo Miccoli; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2007-09-04       Impact factor: 5.958
View more
  8 in total

1.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

2.  Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs.

Authors:  Mio Kitano; Reza Rahbari; Erin E Patterson; Yin Xiong; Nijaguna B Prasad; Yongchun Wang; Martha A Zeiger; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2011-05-07       Impact factor: 5.344

3.  The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.

Authors:  Augustas Beiša; Mindaugas Kvietkauskas; Virgilijus Beiša; Mindaugas Stoškus; Elvyra Ostanevičiūtė; Eugenijus Jasiūnas; Laimonas Griškevičius; Kęstutis Strupas
Journal:  Langenbecks Arch Surg       Date:  2017-02-03       Impact factor: 3.445

4.  BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.

Authors:  Ahmet Şahpaz; Binnur Önal; Ahmet Yeşilyurt; Ünsal Han; Tuncay Delibaşı
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

5.  DNA copy number variations characterize benign and malignant thyroid tumors.

Authors:  Yan Liu; Leslie Cope; Wenyue Sun; Yongchun Wang; Nijaguna Prasad; Lauren Sangenario; Kristen Talbot; Helina Somervell; William Westra; Justin Bishop; Joseph Califano; Martha Zeiger; Christopher Umbricht
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

6.  False-negative results with the Bethesda System of reporting thyroid cytopathology: predictors of malignancy in thyroid nodules classified as benign by cytopathologic evaluation.

Authors:  Bryan K Richmond; Rudy Judhan; Benny Chong; Adam Ubert; Zachary AbuRahma; William Mangano; Stephanie Thompson
Journal:  Am Surg       Date:  2014-08       Impact factor: 0.688

7.  Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.

Authors:  Rupendra T Shrestha; Maria R Evasovich; Khalid Amin; Angela Radulescu; Tina S Sanghvi; Andrew C Nelson; Maryam Shahi; Lynn A Burmeister
Journal:  Thyroid       Date:  2016-07-12       Impact factor: 6.568

8.  Well-differentiated thyroid carcinomas: management of the central lymph node compartment and emerging biochemical markers.

Authors:  Meei J Yeung; Janice L Pasieka
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.